directors and executive officers
Amount not stated
Customary indemnification agreements with the directors and executive officers of Humacyte following the Merger.
With Humacyte
Open in proxy
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Customary indemnification agreements with the directors and executive officers of Humacyte following the Merger.
Services agreements (May 2022 and June 2023) for a study of outcomes of dialysis patients; company paid for clinical research services performed under them.
Master services agreement (June 2024) under which Frenova performs clinical research services for the V012 Phase 3 clinical trial.
Service agreement (July 2024) under which Frenova conducts a study of hemodialysis patient data in certain European countries; company paid for services in 2023.
Distribution agreement (June 2018, as amended) giving Fresenius Medical Care a right to receive a royalty on sales of the ATEV distribution product.
Three license agreements, two still in effect; Legacy Humacyte has made payments of license fees and other expenses to Yale.
Loading...
